

# BBTK - ABVV

**NEWS FLASH**

**Johnson & Johnson  
Innovative Medicine**



## Special Works Council

08 October 2024

Dear colleagues,

On Monday afternoon, 7 October, the following departments were announced that have a potential impact within J&J Innovative Medicine Belgium. On Tuesday morning, 8 October, the relevant departments and individuals were informed about this.

Departments involved:

- 1) Government Affairs & Policy (GAP):** 1 Exempt
- 2) Communicable Diseases:** 2 Exempts
- 3) DPDS- PSTS:** 15 Exempts and 19 Non- Exempts
  - BDDS: 2 Exempts
  - GTSP: 7 Exempts
  - IVSSO: 1 Exempt and 7 Non-Exempts
  - TPPIT: 2 Exempts and 3 Non-Exempts
  - Pathbio: 9 Non-Exempts
  - NCSPSL: 3 Exempts
- 4) DPDS-Therapeutics Discovery (TD):** 9 positions
  - Biologics Discovery: 3 Exempts en 5 Non-Exempts
  - In silico Discovery: 1 Exempt
- 5) Global Development:** 4 positions
  - DU MA: 1 Exempt
  - IDAR: 3 Exempts
- 6) Global regulatory Affairs (GRA):** 1 Exempt
- 7) Neuroscience(NS) – TA Clinical Development:** 1 Exempt
- 8) Global Commercial Strategy Organization (GCSO):** 2 positions
  - Immunology: 1 Exempt
  - Global Market Access: 1 Exempt
- 9) Business Development:** 1 Non-Exempt and 1 Exempt
- 10) International Pharmacovigilance (IPV-OCMO):** 1 Exempt

A total of **57 positions** were listed today.

The total announced potential impact comes to **130 positions**.

The information and consultation phase will continue at subsequent BORs that will take place on 8, 16, 23 and 30 October.

We will keep you informed of the further progress.

You can always reach out to us if you have any questions or need support.

Kind regards,

Your BBTK delegation

